AstraZeneca slips after FDA panel rejects breast cancer drug camizestrant

Investing.com Gold reports: AstraZeneca slips after FDA panel rejects breast cancer drug camizestrant. Full body text was unavailable at ingest time, so this brief is based on headline context.